Can a 5-Day Fast Add to DASH for Blood Pressure?

A medically supervised 5-day fast followed by a modified DASH diet may lower systolic blood pressure more durably than DASH alone in adults with metabolic syndrome. In one randomized trial, the advantage remained at 3 months after researchers accounted for changes in antihypertensive medications. That makes the result worth attention—but it does not show that fasting lets patients safely stop blood-pressure drugs.

The more interesting scientific wrinkle is that fasting caused a large shift in gut-microbiome composition, then much of that shift faded after refeeding while the blood-pressure benefit persisted. The microbiome may help start the process, but it does not yet explain what maintains it.

What the trial actually tested

The primary evidence comes from Maifeld et al.'s 2021 randomized trial, a substudy of NCT02099968. Researchers assigned 71 adults who met criteria for metabolic syndrome to one of two active interventions: 35 participants received 5 days of supervised fasting followed by 3 months of a modified DASH diet, while 36 began the modified DASH diet without fasting.

The groups started out similar. Mean systolic blood pressure was 136±15 mmHg in the fasting-plus-DASH group and 138±16 mmHg in the DASH-only group. Mean body-mass index was 34±4.9 versus 33±4.7 kg/m². This was not a fasting-versus-junk-food comparison. Both groups received a dietary pattern designed to lower blood pressure, which makes the between-group difference an estimate of fasting's added contribution above DASH.

At the 3-month assessment, the fasting-plus-DASH group had a sustained systolic blood-pressure benefit that the DASH-only group did not achieve. The researchers tracked antihypertensive medication-regimen changes and found that the result remained after statistical adjustment for medication titration. The study excerpt available here does not report the exact between-group systolic-pressure difference, confidence interval, formal between-group P value, or the number of medication changes. Those missing details limit how precisely clinicians can judge the size of the effect.

Still, the design answers one narrow question well: in this small group of adults with metabolic syndrome, starting a modified DASH program with a supervised 5-day fast produced a better 3-month systolic-pressure result than starting DASH alone, and medication adjustments do not appear to explain the difference.

DASH deserves credit too

DASH is not background scenery in this experiment. It is an established blood-pressure intervention, and the dietary phase probably contributed substantially to outcomes in both groups. A 2024 randomized trial of DASH with or without time-restricted eating found that DASH alone produced clinically meaningful systolic-pressure reductions in people with stage 1 primary hypertension.

That study tested a different population and a different fasting pattern, so it cannot tell us whether a 5-day fast would help the participants in Maifeld et al. But it prevents an easy, wrong reading of the earlier trial: the fasting arm did not succeed because it received the only useful diet. It added fasting to a dietary program that can lower blood pressure on its own.

Broader fasting research supports cautious interest rather than certainty. A 2025 BMJ network meta-analysis compared alternate-day fasting, time-restricted eating, whole-day fasting, continuous energy restriction, and unrestricted diets for body weight and cardiometabolic risk factors. A separate 2024 systematic review of intermittent fasting plus exercise also evaluated systolic and diastolic blood pressure among other cardiometabolic outcomes.

Neither synthesis turns this specific protocol into standard care. Most intermittent-fasting research involves eating windows, intermittent low-calorie days, or other regimens that differ materially from a complete, supervised 5-day fast followed by months of modified DASH eating. Duration, calories, refeeding, medical monitoring, and baseline medication use all matter.

The microbiome changed fast. The pressure benefit lasted longer.

Fasting produced a major change in gut-microbial community composition in the fasting group (PERMANOVA P=0.001). DASH alone did not produce a statistically significant compositional change over 3 months (PERMANOVA P=0.374). The analysis used multiple-testing correction and effect-size methods, and the paper identified changes in taxa that included Akkermansia and members of Ruminococcaceae, groups often discussed in relation to short-chain-fatty-acid production.

That finding is biologically plausible. A 2025 systematic review and meta-analysis of prebiotic interventions concluded that interventions intended to modify gut microbes were associated with lower systolic and diastolic blood pressure. Fiber and prebiotics are not fasting, however, and a change in stool microbes does not prove that microbes caused a person's blood pressure to fall.

In the fasting trial, the microbial composition partially moved back toward its pre-fast state during the following 3 months, while the systolic-pressure benefit remained. That mismatch is the key limitation of the mechanism story. The microbiome could be an early trigger, a marker of other metabolic changes, or one contributor among several. It is not established as the durable driver of the blood-pressure effect.

The investigators also tested whether a fasting-related microbial signature could predict blood-pressure responsiveness in a separate cohort of 15 healthy volunteers. The signature generalized in that small cohort, which supports the hypothesis. But the volunteers were healthy and apparently male-only, unlike the metabolic-syndrome trial population. A prediction signal in 15 people is a lead for future research, not a clinical test.

Why the result needs replication

The randomized comparison is a strength, as is the active DASH comparator and medication tracking. The trial remains small: 35 people received fasting plus DASH and 36 received DASH alone. That sample cannot reliably detect uncommon harms, identify which antihypertensive drug regimens require the most adjustment, or settle whether sex, baseline blood pressure, or metabolic-syndrome severity changes the response.

It also does not establish medication reduction. Adjusting for medication changes is not the same as documenting that participants discontinued drugs or reduced their doses. No conclusion about deprescribing follows from this study.

There is a broader evidence gap as well. The available literature does not include a retrieved null or negative randomized trial of prolonged fasting for blood pressure in medicated hypertensive adults. Absence of a trial in a review set is not evidence that unfavorable results do not exist. The field needs larger, independently run studies with prespecified blood-pressure outcomes, detailed medication data, adverse-event reporting, and follow-up beyond 3 months.

For perspective, lifestyle treatment remains the foundation of metabolic-syndrome management. A 2026 systematic review and meta-analysis found that diet, exercise, and combined lifestyle approaches can improve metabolic-syndrome severity in adults with overweight or obesity. The fasting trial should be viewed as a possible addition to that foundation, not a replacement for established care.

Who should—and should not—act on this now

A 5-day fast while taking antihypertensive medication is a medical intervention. Fasting can compound medication-related blood-pressure lowering and may create risks related to hypotension, electrolytes, cardiac rhythm, and refeeding. The trial protocol involved supervision; an unsupervised home fast is a different intervention with unknown safety.

If you take blood-pressure medication, do not use this study as a reason to reduce or stop it. Discuss any fast with the clinician managing your medications, especially if you have diabetes, kidney disease, cardiovascular disease, a history of eating disorders, or symptoms of low blood pressure.

The practical lesson is less glamorous than a microbiome makeover: sustained dietary adherence matters. The studied program paired fasting with 3 months of modified DASH eating. It did not test five days of fasting followed by a return to usual habits.

For now, the evidence supports a measured conclusion. One small randomized trial found a lasting systolic blood-pressure advantage from a supervised 5-day fast followed by modified DASH, beyond DASH alone and independent of medication adjustment. The effect deserves replication. The mechanism remains unsettled, and the protocol requires medical supervision—not a long weekend, a water bottle, and misplaced confidence.